-
Children's medicine welcomes the policy dividend again, and the market space is becoming wider and wider
Time of Update: 2021-12-06
Under the policy-guided research and development of children's drugs and the liberalization of the "three-child policy", the industry predicts that the market size of children's drugs will continue to maintain an average annual growth rate of more than double digits for a long time to come .
-
The R&D investment of local pharmaceutical companies is still "in full swing", and multinational pharmaceutical companies are also "heating up"
Time of Update: 2021-12-06
" Over 80% of the A-share listed pharmaceutical companies had increased their total R&D investment in the first three quarters compared with the same period last year .
-
Comprehensive layout, multi-point blossom, new diabetes drug research and development, domestic pharmaceutical companies continue to appear
Time of Update: 2021-12-06
In recent years, Chinese pharmaceutical companies have gradually appeared in the research and development queue of new diabetes drugs, including Shanghai Renhui Biopharmaceuticals, Hausen Pharmaceuticals, Microchip Biopharmaceuticals, Hengrui Pharmaceuticals, Hualing Pharmaceuticals, Tonghua Dongbao, East China Pharmaceuticals, Ganli Pharmaceuticals, etc.
-
Gao Xuemin, independent director of Watson Pharmaceuticals, leaves Li Hui as candidate for by-election
Time of Update: 2021-12-06
On November 17, Watson Pharmaceuticals issued an announcement stating that as his term of office expires on November 15, Gao Xuemin will no longer serve as independent director of the company’s second board of directors and chairman of the second board’s nomination committee, and his resignation will be in Effective from the day when the company’s general meeting of shareholders elects new independent directors .
-
Where is the development of drugs for systemic lupus erythematosus?
Time of Update: 2021-12-06
Figure 2 The incidence of systemic lupus erythematosus in different regions (1975~2000)Treatment strategyTreatment strategyPrevention, reduction of recurrence and control of organ damage caused by disease, reduction of patient mortality, improvement of survival rate and quality of life are the long-term goals of SLE treatment .
-
The domestic innovative drug track is becoming more and more "involved", what should pharmaceutical companies do?
Time of Update: 2021-12-06
Some popular tracks such as ADC drugs and PD-1 products are becoming more and more "involved", more and more companies are entering the game, and the amount of fundraising and financing is also increasing, and the competition is fierce .
-
my country's orthopedic equipment market has a bright future, and it is expected to exceed 50 billion yuan in 2023
Time of Update: 2021-12-06
At present, driven by multiple factors such as the continuous promotion of favorable policies and the continuous advancement of science and technology, the market capacity of orthopedic medical equipment in China is showing a trend of continuous expansion .
Among them, the orthopedic implant market scale was 36 billion yuan, a year-on-year increase of 16.
-
Over 300 million people in my country have sleep disorders, and the market for sleep aids is promising
Time of Update: 2021-12-06
Recently, China Galaxy Securities pointed out in its research report that the growth of sleep aid products for medical and health care products can be expected .
The penetration rate of medical and health products in the sleep economy of Chinese people is relatively low, accounting for only about 20%.
-
FDA delays Bristol-Myers Squibb's first-in-class cardiomyopathy drug listing application
Time of Update: 2021-12-06
The Phase III clinical results, code-named EXPLORER-HCM, showed that compared with the placebo group, Mavacamten showed clinically significant improvements in symptoms, functional status and quality of life in patients with symptomatic oHCM, reaching all primary and secondary clinical endpoints .
-
Sichuan Province issued an important notice, the purchase of oral consumables with quantity or started
Time of Update: 2021-12-06
At present, the Sichuan Pharmaceutical Equipment Bidding and Purchasing Service Center has officially started the information declaration work for the maintenance of dental implants and repair abutment medical consumables.
-
Hillhouse adjusted its positions substantially in the third quarter, and the first three warehouses were all biopharmaceutical companies
Time of Update: 2021-12-06
In the third quarter of this year, BeiGene is still a major position in Hillhouse's US stocks .
In the F13 documents for the third quarter, BeiGene became a major position in Hillhouse's stock holdings, holding 5,472,300 shares, corresponding to a market value of US$1.
-
Diabetes digital management problems need to be solved urgently, and pharmaceutical companies are actively exploring and trying
Time of Update: 2021-12-06
Diabetes, as one of the four chronic diseases that the "Healthy China Action (2019-2030)" focuses on prevention and control, has become an important chronic disease threatening human health . Accor
-
The second domestically produced generic drug!
Time of Update: 2021-12-06
It is reported that Hausen Pharmaceutical's fulvestrant is the second generic fulvestrant that was declared and approved by a Chinese company .
Now, after Tianqing, Hausen Pharmaceutical's fulvestrant has become the second domestic generic drug .
-
Industry: In the next 5 to 10 years, the level of China's medical equipment may be equal to that of Europe
Time of Update: 2021-12-06
In addition, in the past, China's medical equipment industry lacked some reasonable and stable incentive policies for the research and development of domestic equipment.
In addition, relevant and continuous incentive policies are also needed to encourage and support domestic pharmaceutical equipment companies to in-depth research and develop original products .
-
With the rapid development of the life science industry, pharmaceutical equipment and consumables usher in a large increase in demand
Time of Update: 2021-12-06
In the context of the rapid development of the life science industry, its upstream industry chain, including related equipment, consumables, raw materials and services, has also ushered in a large increase in demand .
-
Tap into the overseas PD-1/L1 monoclonal antibody market Livzon Group "follows the trend" and enters the game
Time of Update: 2021-12-06
According to the agreement, Livzumab will license the recombinant humanized anti-PD-1 monoclonal antibody for injection (LZM009) with independent intellectual property rights (LZM009) to BPTx for a paid and non-exclusive license for the development of new PD-1 targeted immune cytokines (PD- 1 ICs), while authorizing LZM009 to BPTx for the development and commercialization of PD-1 ICs drugs in regions other than Greater China .
-
The flow of talents in the pharmaceutical market accelerates the current senior management changes of more than 200 pharmaceutical companies during the year
Time of Update: 2021-12-06
More than 10 companies including Hengrui Pharmaceutical, Lexin Medical, Wantai Bio, Kanghong Pharmaceutical, and Ruizhi Pharmaceutical have issued announcements on the resignation of senior executives .
-
New crown drug made in China?
Time of Update: 2021-12-06
At the same time, there are few small molecule CDMO companies that can meet the production capacity of Pfizer's new crown drug, and Kailaiying is one of them .
-
ED generic drugs have quality problems!
Time of Update: 2021-12-06
Now, this company is in big trouble!According to the latest enforcement report of the US FDA, the Mumbai-based Indian pharmaceutical giant is recalling over 110,000 bottles of tadalafil generic drugs in the US market through its US branch due to production quality problems .
-
"Star drug" "Engliflozin" new indications for marketing application accepted
Time of Update: 2021-12-06
On September 30 this year, Eli Lilly issued a press release stating that it had submitted an application to CDE for the registration of new indications for adult patients with heart failure with enpagliflozin for ejection fraction preservation .
